Ron Johnson Highlights Critical Drug Supply Chain Vulnerabilities from China

Critical Vulnerabilities in Drug Manufacturing

• ⚠️ Senator Ron Johnson expresses deep concern over the U.S. dependence on China for API and precursor chemicals, a vulnerability first identified in 2020.
• 📌 The current infrastructure bill is criticized for failing to address this critical issue, despite its importance.
• 💡 The core problem lies in bringing manufacturing back to the U.S. where it can be properly inspected, a task complicated by expensive permitting for refineries.

Proposed Solutions and First Steps

• 🏷️ A simple labeling requirement for drug origin is proposed as a way to pressure companies into reshoring manufacturing.
• ⚖️ The idea is that transparency would create market pressure, rewarding high-quality manufacturers and penalizing low-quality ones, thus fixing a broken market.
• 🚫 Existing laws are not being enforced due to the fear of creating drug shortages, necessitating a phased approach to weaning off problematic supply chains.

Economic and Market Dynamics

• 💰 Economic coercion from China keeps key starting material prices artificially low through subsidies and other means.
• 📈 Implementing measures like anti-dumping duties (80 CVD) against Chinese KSMs could help create a viable U.S. domestic market.
• 🏭 Continuous flow manufacturing capabilities exist in the U.S. for critical materials like heparin, but investment is needed.

Enhancing Supply Chain Resiliency

• 🔑 A market-based resiliency benchmark is suggested as a positive incentive, rewarding facilities with consistent inspection passes and secure supply chains.
• 🏥 Starting with hospital systems and hospital-use drugs is proposed as a manageable initial step.
• 🗣️ The importance of whistleblowers is emphasized to expose instances where quality issues were overlooked, thereby enabling law enforcement.
• 📢 Public awareness of U.S. vulnerability is crucial for gaining congressional support for necessary legislative action.